Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC50 of ropivacaine for PENG+LFCN vs supra-inguinal FICB in total hip arthroplasty
ChiCTR2300071319Phase 4Not yet recruiting
- Sponsor
- Funing County People's Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ropivacaine in hip fracture and postoperative pain (2 arms), sponsored by Funing County People's Hospital. Primary endpoints: Postoperative pain intensity (VAS score) and EC50 of ropivacaine by sequential approach. Planned start May 2023; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
hip fracturepostoperative pain
Beyond the preview
Go deeper on ChiCTR2300071319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071319.